AAO LIVE: Researchers target risk factors for development of rhegmatogenous retinal detachments

In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, William Kearney and Dan Gong, MD, discussed how patients with a unilateral retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.

COVID-19-imposed health care restrictions had no negative effects on status of DME

DME showed small significant improvement in study cohort.

Pooled Phase 3 data reports safety, efficacy, reduced treatment burden with faricimab compared with aflibercept for the treatment of nAMD

The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.

AAO LIVE: Study finds retinal detachment rates unaffected by early treatment with intravitreal antivirus or vitrectomy in patients with acute retinal necrosis

October 02, 2022

In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Ines Lains, MD, PhD, detailed how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy did not improve the rates of retinal detachment in patients diagnosed with acute retinal necrosis.

Center-involved DME resolves faster with faricimab than aflibercept

October 02, 2022

The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.

AAO: Janssen announces late-breaking data from a pair of gene therapy programs

October 02, 2022

In an announcement at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, the company noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.

EP. 2: EyeCon 2022: Location, location, location and bring the family

September 28, 2022

The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.